.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
UBS
US Department of Justice
Julphar
Fuji
Farmers Insurance
McKinsey
Cipla
Healthtrust
Medtronic

Generated: June 29, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,965,592

« Back to Dashboard

Details for Patent: 5,965,592

Title: Acyl compounds
Abstract:Compounds of the formula ##STR1## and their salts, in which R.sub.1, is a C.sub.1 -C.sub.7 aliphatic hydrocarbon radical; X.sub.1 is --CO; X.sub.2 is a divalent aliphatic hydrocarbon radical which comprises an ethyl group and an alkylene of 2 to 6 carbon atoms; R.sub.2 is hydroxy, carboxy or alkoxycarbonyl in which alkoxy is from 1 to 7 carbon atoms; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl or 5-tetrazolyl; and the rings A and B independently of one another are otherwise unsubstituted; can be prepared in a known manner and may be used as active ingredients for medicaments.
Inventor(s): Buhlmayer; Peter (Arlesheim, CH), Ostermayer; Franz (Riehen, CH), Schmidlin; Tibur (Basel, CH)
Assignee: Novartis Corporation (Summit, NJ)
Filing Date:Jul 29, 1998
Application Number:09/124,520
Claims:1. A compound of the formula: ##STR11## in which R1 is alkyl of 1 to 7 carbon atoms;

R2 is hydroxy, carboxy, or alkoxycarbonyl in which alkoxy having from 1 to 7 carbon atoms;

R3 is carboxy or 1H-tetrazol-5-yl; and

X.sub.4 and X.sub.5 taken together are alkylene of 2 to 6 carbon atoms, or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 in which

R1 is CH.sub.3 CH.sub.2 CH.sub.2 --, CH.sub.3 CH.sub.2 CH.sub.2 CH.sub.2 --, or CH.sub.3 CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 --;

R2 is --COOH, --COOCH.sub.3, or --COOCH.sub.2 CH.sub.3 ; and

X.sub.4 and X.sub.5 taken together are --(CH.sub.2).sub.4 -- or --(CH.sub.2).sub.5 --.

3. The compound according to claim 1 in which R1 is CH.sub.3 CH.sub.2 CH.sub.2 CH.sub.2 -- and X.sub.4 and X.sub.5 taken together are --(CH.sub.2).sub.4 --.

4. The compound according to claim 1 in which R1 is CH.sub.3 CH.sub.2 CH.sub.2 CH.sub.2 -- and X.sub.4 and X.sub.5 taken together are --(CH.sub.2).sub.5 --.

5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1.

6. A method of treating hypertension in a warm blooded animal comprising administering to an animal in need of such treatment an effective amount of a compound according to claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
US Department of Justice
Covington
Medtronic
Cerilliant
Harvard Business School
Boehringer Ingelheim
AstraZeneca
Daiichi Sankyo
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot